Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
563 stopped studies mapped to Malignant Pancreatic Neoplasm and descendants · 93% state a reason
Over the 563 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT01025570 | A Study Evaluating Gemcitabine Plus Bosutinib for Patients With Resected Pancreatic Cancer | Phase 1 | terminated | Dec 3, 2009 | University of California, San Francisco | Terminated due to slow accrual | Enrollment / accrual |
| NCT00878657 | Intensity-Modulated Radiation Therapy and Gemcitabine in Treating Patients With Locally… | Phase 1 | terminated | Apr 9, 2009 | Rutgers, The State University of New Jersey | Slow accrual | Enrollment / accrual |
| NCT01233505 | Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Nov 3, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00101907 | Safety of AMG 706 Plus Panitumumab Plus Gemcitabine-Cisplatin in the Treatment of… | Phase 1 | terminated | Jan 19, 2005 | Amgen | Study terminated per recommendation of Data Review Team | Other (stated, no rule matched) |
| NCT00003434 | Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic… | Phase 1 | terminated | Apr 27, 2004 | Duke University | not stated | Not stated |
| NCT00553813 | A Phase II Trial of TPI 287 in Patients Advanced, Unresectable Pancreatic Cancer | Phase 2 | terminated | Nov 6, 2007 | Cortice Biosciences, Inc. | Insufficient funding | Funding |
| NCT00636883 | Oxaliplatin, Gemcitabine, and Erlotinib Study in Patients With Advanced Chemo-naïve…(GEMOX-T) | Phase 2 | terminated | Mar 17, 2008 | National Guard Health Affairs | slow accrual rate | Enrollment / accrual |
| NCT01096732 | Hedgehog Inhibition for Pancreatic Ductal Adenocarcinoma (PDAC) in the Preoperative…(HIPPoS) | Phase 2 | terminated | Mar 31, 2010 | Lisa Bax | Slow recruitment | Enrollment / accrual |
| NCT00613730 | Adenocarcinoma of the Pancreas Treated With Panitumumab and Gemcitabine Regimen to…(APPRISE 1) | Phase 2 | terminated | Feb 13, 2008 | Amgen | APPRISE closure prompted by SWOG S0205 not meeting primary endpoint-improving OS. APPRISE… | Safety / toxicity |
| NCT00005591 | Cetuximab Plus Gemcitabine in Treating Patients With Locally Advanced, Metastatic, or… | Phase 2 | withdrawn | Aug 9, 2004 | University of Alabama at Birmingham | not stated | Not stated |
| NCT01192763 | RO4929097 Before Surgery in Treating Patients With Pancreatic Cancer | Phase 1 | terminated | Sep 1, 2010 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01830322 | Safety and Effectiveness Study of CPI-613 and/or Gemcitabine to Treat Metastatic… | Phase 2 | withdrawn | Apr 12, 2013 | Cornerstone Pharmaceuticals | not stated | Not stated |
| NCT00003514 | Antineoplaston Therapy in Treating Patients With Neuroendocrine Tumor That Is Metastatic… | Phase 2 | withdrawn | Jan 27, 2003 | Burzynski Research Institute | not stated | Not stated |
| NCT00896467 | Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer… | — | terminated | May 11, 2009 | Centre Oscar Lambret | not stated | Not stated |
| NCT01282333 | Veliparib, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Advanced… | Phase 1 | terminated | Jan 25, 2011 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT01600807 | OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the… | Phase 1 / Phase 2 | withdrawn | May 17, 2012 | Dana-Farber Cancer Institute | Study was pending major changes and was on hold, pending activation; administratively withdrawn;… | Other (stated, no rule matched) |
| NCT00587132 | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | terminated | Jan 7, 2008 | Mayo Clinic | Lack of funding | Funding |
| NCT01017822 | Conatumumab, Gemcitabine Hydrochloride, Capecitabine, and Radiation Therapy in Treating… | Phase 1 / Phase 2 | withdrawn | Nov 23, 2009 | Radiation Therapy Oncology Group | This study was withdrawn due to study agent availability. | Other (stated, no rule matched) |
| NCT00049608 | Gemcitabine Combined With Mistletoe in Treating Patients With Advanced Solid Tumors | Phase 1 | terminated | Jan 27, 2003 | National Center for Complementary and Integrative Health (NCCIH) | Principal investigator \[PI\] has left institution. | Investigator |
| NCT00671463 | Pancreatic Stent to Prevent Leak After Distal Pancreatectomy(LEAPS) | N/A | withdrawn | May 5, 2008 | Massachusetts General Hospital | Anticipated high risk of pancreatitis | Other (stated, no rule matched) |
| NCT00084461 | Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors | Phase 2 | terminated | Jun 11, 2004 | National Cancer Institute (NCI) | not stated | Not stated |
| NCT00012246 | Vaccine Therapy in Treating Patients With Cancer of the Gastrointestinal Tract | Phase 2 | terminated | Jan 27, 2003 | The University of Texas Medical Branch, Galveston | Administratively Terminated | Other (stated, no rule matched) |
| NCT01707758 | Detection of Cancer-Specific Active Proteases in Blood Via Fluorescence | — | withdrawn | Oct 16, 2012 | University of Kansas | Trial terminated - Nanoscale Company out of business | Sponsor / business decision |
| NCT00662688 | Chemotherapy With or Without Dalteparin in Treating Patients With Metastatic Pancreatic…(PAM07) | Phase 3 | terminated | Apr 21, 2008 | GERCOR - Multidisciplinary Oncology Cooperative Group | recruitment prematurely stopped due to a lack of eligible patients. | Enrollment / accrual |
| NCT00959946 | Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic… | Phase 1 / Phase 2 | terminated | Aug 17, 2009 | Pfizer | not stated | Not stated |
| NCT01401387 | Pancreatic Enzyme Suppletion in Pancreatic Cancer(EPC) | Phase 4 | withdrawn | Jul 25, 2011 | Foundation for Liver Research | study never started | Other (stated, no rule matched) |
| NCT00003851 | Gemcitabine Compared With Pancreatic Enzyme Therapy Plus Specialized Diet (Gonzalez… | N/A | terminated | Jan 27, 2003 | Columbia University | Approval lapse | Other (stated, no rule matched) |
| NCT00564720 | Gemcitabine Plus Erlotinib Versus Erlotinib Plus Gemcitabine Plus Oxaliplatin, in… | Phase 2 | terminated | Nov 28, 2007 | Hellenic Oncology Research Group | Due to poor accrual of the study | Enrollment / accrual |
| NCT00524069 | Gemcitabine, Capecitabine, and Bevacizumab in Treating Patients With Pancreatic Cancer… | N/A | withdrawn | Sep 3, 2007 | Roswell Park Cancer Institute | Withdrawn due to no accrual | Enrollment / accrual |
| NCT00087191 | EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or… | N/A | terminated | Jul 12, 2004 | National Cancer Institute (NCI) | Administratively complete. | Other (stated, no rule matched) |
| NCT01071434 | Feasibility of Using Real-time Cine-MRI for Treating Moving & Deforming Tumors | — | terminated | Feb 19, 2010 | Stanford University | PI left | Investigator |
| NCT00387348 | Escitalopram in Treating Depression in Patients With Advanced Lung or Gastrointestinal… | Phase 3 | terminated | Oct 13, 2006 | Massachusetts General Hospital | DSMB stopped study because placebo arm had more adverse events | Safety / toxicity |
| NCT00027521 | Electroporation Therapy With Bleomycin in Treating Patients With Pancreatic Cancer | Phase 1 | withdrawn | Nov 21, 2003 | Ichor Medical Systems Incorporated | Program terminated | Other (stated, no rule matched) |
| NCT00410774 | Gemcitabine and Bevacizumab in Treating Patients With Pancreatic Cancer That Has Been… | Phase 1 / Phase 2 | terminated | Dec 13, 2006 | University of California, San Francisco | low accrual-no data available | Enrollment / accrual |
| NCT00025532 | Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Gastrointestinal Cancer | Phase 1 | withdrawn | Nov 21, 2003 | University of California, San Francisco | not stated | Not stated |
| NCT00855634 | Resection in Pancreatic Cancer With Minimal Metastatic Disease or Venous Infiltration…(PaMeViTUM) | N/A | terminated | Mar 4, 2009 | Technical University of Munich | Protocol planned interim analysis after two years showed very low recruitment in cohort 1 and low… | Efficacy / futility |
| NCT01094600 | Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to… | N/A | withdrawn | Mar 29, 2010 | Columbia University | not stated | Not stated |
| NCT01031056 | Collection of Biospecimen & Clinical Information in Patients w/ Gastrointestinal Cancers | — | withdrawn | Dec 14, 2009 | Stanford University | Change in research focus | Other (stated, no rule matched) |
| NCT00831493 | Vorinostat Plus Radiation Therapy in Pancreatic Cancer | Phase 1 / Phase 2 | terminated | Jan 29, 2009 | M.D. Anderson Cancer Center | Slow Accrual. | Enrollment / accrual |
| NCT01212887 | Treated Blood Cells, Cyclophosphamide, Fludarabine Phosphate, and Aldesleukin in Treating… | Phase 1 | terminated | Oct 1, 2010 | Cancer Research UK | due to safety concerns and lack of efficacy | Safety / toxicity |
| NCT00967291 | Mitomycin C and Ifosfamide in Treating Patients With Metastatic Pancreatic Cancer(PACT-11) | Phase 2 | terminated | Aug 27, 2009 | IRCCS San Raffaele | lack of activity and G3-4 toxicity at interim analysis | Safety / toxicity |
| NCT00593008 | Temsirolimus in Combination With Gemcitabine in Previously Untreated Metastatic… | Phase 1 | terminated | Jan 14, 2008 | Massachusetts General Hospital | not stated | Not stated |
| NCT00281996 | Imatinib Mesylate and Gemcitabine in Treating Patients With Locally Advanced, Metastatic,… | Phase 1 | terminated | Jan 25, 2006 | Northwestern University | Closed to accrual to allow enrollment on another more promising trial. | Enrollment / accrual |
| NCT00683085 | Human Leukocyte Antigen-A*02:01-restricted Tumor Vessel Specific Peptide Vaccination for… | Phase 1 / Phase 2 | terminated | May 23, 2008 | Tokyo University | Lack of eligible patient | Other (stated, no rule matched) |
| NCT00898781 | Study of Circulating Cancer Cells in Patients With Metastatic Breast, Ovarian, Colon, or… | — | terminated | May 12, 2009 | Mayo Clinic | Due to poor accrual | Enrollment / accrual |
| NCT00658801 | Study of Respiratory Gated Proton Beam Radiotherapy for Inoperable Pancreas Carcinoma | Phase 1 | terminated | Apr 15, 2008 | National Cancer Center, Korea | difficult to register | Other (stated, no rule matched) |
| NCT00415454 | Study Combining Suicide Gene Therapy With Chemoradiotherapy in the Treatment of… | Phase 1 | terminated | Dec 25, 2006 | Henry Ford Health System | Poor enrollment | Enrollment / accrual |
| NCT00550004 | Phase II Study to Evaluate Efficacy and Safety of RP101 in Combination With Gemcitabine(RP101) | Phase 2 | terminated | Oct 26, 2007 | SciClone Pharmaceuticals | not stated | Not stated |
| NCT00326911 | Cetuximab and Bevacizumab With or Without Gemcitabine to Treat Metastatic Pancreatic… | Phase 2 | terminated | May 17, 2006 | Eli Lilly and Company | The planned enrollment was 130 patients and the study was halted prematurely due to lack of… | Efficacy / futility |
| NCT01330823 | L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)(CARPAN) | Phase 3 | suspended | Apr 7, 2011 | University Medicine Greifswald | after interims analysis standard errors for inflammatory and nutritional markers varied widely,… | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated May 9, 2014source: clinicaltrials